MSD Entered into a Clinical Trial Collaboration with SOTIO to Evaluate SOT101 + Keytruda (pembrolizumab) for the Treatment of Solid Tumors
Shots:
- The companies collaborated to evaluate the efficacy and safety of SOTIO’s SOT101 (IL-15 superagonist) + MSD’s Keytruda in the P-II (AURELIO-04) study in 300 patients with selected advanced/refractory solid tumors across the US & EU for six different indications. The study is expected to initiate in H1’22
- SOT101 + Keytruda showed promising clinical efficacy across multiple indications in the ongoing P-I/Ib (AURELIO-03) study
- SOT101 demonstrated a strong preclinical in vivo efficacy in multiple tumor models that showed increased long-term survival and tumor regression along with a favorable toxicology profile
Ref: Globe Newswire | Image: MSD
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com